Vimta Labs Limited — PPTs, 06-05-2026: Investor Presentation

Vimta Labs reported robust performance for the quarter and the full fiscal year. For the quarter, total income grew 15.2% year-over-year to Rs 112 Cr, with PAT rising 15.2% to Rs 21.1 Cr. Quarterly EPS was Rs 4.7. For the full fiscal year, total income increased 19.5% YoY to Rs 416.3 Cr, and PAT improved 16.1% to Rs 77.5 Cr, with an annual EPS of Rs 17.4. Vimta Labs leads India's Pharma Analytical and Food Testing sectors, with significant overseas revenue from Pharma Analytical (36%) and Clinical Research (75%).

Key strategies involve capacity expansions, service innovations, and new market penetration. Management is focused on operational excellence, talent acquisition, and advanced technology. The outlook is positive, driven by growing demand for safe and quality drugs, food, electronics, and a cleaner environment. The company's total Capex of Rs 99.8 Cr for the fiscal year underscores its investment in future growth.